NovoCure (NVCR) Gross Profit (2014 - 2026)
NovoCure (NVCR) posted Gross Profit of $142.5 million for Q2 2026, up 5.44% sequentially from $135.1 million in Q1 2026, and up 21.43% YoY from $117.3 million in Q2 2025.
NovoCure (NVCR) Gross Profit (2014 - 2026) Analysis & Trends
NovoCure has reported Gross Profit for 13 years, with the latest figure at $142.5 million in Q2 2026.
- Quarterly Gross Profit rose 21.43% year-over-year to $142.5 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $532.3 million (up 10.58% YoY) and the FY2025 annual result came in at $488.5 million, up 4.37% from the prior year.
- Gross Profit improved to $142.5 million in Q2 2026 per NVCR's latest filing, from $135.1 million in the prior quarter.
- Over five years, Gross Profit peaked at $142.5 million in Q2 2026 and troughed at $92.0 million in Q2 2023.
- A 5-year average of $113.2 million and a median of $114.0 million in 2022 frame the typical range for Gross Profit.
- The sharpest annual moves came in 2023 and 2024: Gross Profit decreased 18.09% in 2023, then gained 26.25% in 2024.
- Over 5 years, Gross Profit stood at $99.5 million in 2022, then grew by 1.69% to $101.2 million in 2023, then increased by 26.25% to $127.8 million in 2024, then advanced by 3.44% to $132.2 million in 2025, then rose by 7.78% to $142.5 million in 2026.
- According to Business Quant data, Gross Profit over the past three periods registered $142.5 million, $135.1 million, and $132.2 million for Q2 2026, Q1 2026, and Q4 2025 respectively.
Powered by 
Peer Comparison
Historic Data
Download Data| Date | Value |
|---|---|